Linnaeus Therapeutics raised $1.27 million to advance LNS8801, an FDA-designated orphan drug for the treatment of metastatic cutaneous melanoma, a rare and difficult-to-treat skin cancer.
Linnaeus Therapeutics raised $1.27 million to advance LNS8801, an FDA-designated orphan drug for the treatment of metastatic cutaneous melanoma, a rare and difficult-to-treat skin cancer.